{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:54:10Z","timestamp":1789538050117,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 81001183"],"award-info":[{"award-number":["No. 81001183"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science & Technology Research Project of Returned Visiting Scholar","award":["2015"],"award-info":[{"award-number":["2015"]}]},{"name":"Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences","award":["2021-I2M-1-014"],"award-info":[{"award-number":["2021-I2M-1-014"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-A-165"],"award-info":[{"award-number":["2022-PUMCH-A-165"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-B-039"],"award-info":[{"award-number":["2022-PUMCH-B-039"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The 70-gene signature (70-GS, MammaPrint) test has been recommended by the main guidelines to evaluate prognosis and chemotherapy benefit of hormonal receptor positive human epidermal receptor 2 negative (HR\u2009+\u2009\/Her2\u2212) early breast cancer (BC). However, this expensive assay is not always accessible and affordable worldwide. Based on our previous study, we established nomogram models to predict the binary and quartile categorized risk of 70-GS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed a consecutive cohort of 150 female patients with HR\u2009+\u2009\/Her2\u2212 BC and eligible 70-GS test. Comparison of 40 parameters including the patients\u2019 medical history risk factors, imaging features and clinicopathological characteristics was performed between patients with high risk (N\u2009=\u200962) and low risk (N\u2009=\u200988) of 70-GS test, whereas risk calculations from established models including Clinical Treatment Score Post-5\u00a0years (CTS5), Immunohistochemistry 3 (IHC3) and Nottingham Prognostic Index (NPI) were also compared between high vs low binary risk of 70-GS and among ultra-high (N\u2009=\u200912), high (N\u2009=\u200950), low (N\u2009=\u200965) and ultra-low (N\u2009=\u200923) quartile categorized risk of 70-GS. The data of 150 patients were randomly split by 4:1 ratio with training set of 120 patients and testing set 30 patients. Univariate analyses and multivariate logistic regression were performed to establish the two nomogram models to predict the the binary and quartile categorized risk of 70-GS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared to 70-GS low-risk patients, the high-risk patients had significantly less cardiovascular co-morbidity (p\u2009=\u20090.034), more grade 3 BC (p\u2009=\u20090.006), lower progesterone receptor (PR) positive percentage (p\u2009=\u20090.007), more Ki67 high BC (\u2265\u200920%, p\u2009&lt;\u20090.001) and no significant differences in all the imaging parameters of ultrasound and mammogram. The IHC3 risk and the NPI calculated score significantly correlated with both the binary and quartile categorized 70-GS risk classifications (both p\u2009&lt;\u20090.001). The area under curve (AUC) of receiver-operating curve (ROC) of nomogram for binary risk prediction were 0.826 (C-index 0.903, 0.799\u20131.000) for training and 0.737 (C-index 0.785, 0.700\u20130.870) for validation dataset respectively. The AUC of ROC of nomogram for quartile risk prediction was 0.870 (C-index 0.854, 0.746\u20130.962) for training and 0.592 (C-index 0.769, 0.703\u20130.835) for testing set. The prediction accuracy of the nomogram for quartile categorized risk groups were 55.0% (likelihood ratio tests, p\u2009&lt;\u20090.001) and 53.3% (p\u2009=\u20090.04) for training and validation, which more than double the baseline probability of 25%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>To our knowledge, we are the first to establish easy-to-use nomograms to predict the individualized binary (high vs low) and the quartile categorized (ultra-high, high, low and ultra-low) risk classification of 70-GS test with fair performance, which might provide information for treatment choice for those who have no access to the 70-GS testing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-023-04523-7","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T11:02:59Z","timestamp":1699527779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patients"],"prefix":"10.1186","volume":"21","author":[{"given":"Bo","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingtong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixin","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanna","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songjie","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingli","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7547-1470","authenticated-orcid":false,"given":"Qiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"issue":"1","key":"4523_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"4523_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115\u201332.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"4523_CR3","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1016\/S1470-2045(13)70567-9","volume":"15","author":"L Fan","year":"2014","unstructured":"Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM, Goss PE. Breast cancer in China. Lancet Oncol. 2014;15(7):e279-289.","journal-title":"Lancet Oncol"},{"issue":"3","key":"4523_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"4523_CR5","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1634\/theoncologist.2011-0048","volume":"16","author":"AH Kamal","year":"2011","unstructured":"Kamal AH, Loprinzi CL, Reynolds C, Dueck AC, Geiger XJ, Ingle JN, Carlson RW, Hobday TJ, Winer EP, Goetz MP. Breast medical oncologists\u2019 use of standard prognostic factors to predict a 21-gene recurrence score. Oncologist. 2011;16(10):1359\u201366.","journal-title":"Oncologist"},{"issue":"8","key":"4523_CR6","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","volume":"375","author":"F Cardoso","year":"2016","unstructured":"Cardoso F, van\u2019t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375(8):717\u201329.","journal-title":"N Engl J Med"},{"issue":"2","key":"4523_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111\u201321.","journal-title":"N Engl J Med"},{"issue":"8","key":"4523_CR8","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMra0801289","volume":"360","author":"C Sotiriou","year":"2009","unstructured":"Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360(8):790\u2013800.","journal-title":"N Engl J Med"},{"issue":"6","key":"4523_CR9","doi-asserted-by":"publisher","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","volume":"20","author":"WJ Gradishar","year":"2022","unstructured":"Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, et al. Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(6):691\u2013722.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6871","key":"4523_CR10","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/415530a","volume":"415","author":"LJ van\u2019t Veer","year":"2002","unstructured":"van\u2019t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530\u20136.","journal-title":"Nature"},{"issue":"24","key":"4523_CR11","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1200\/JCO.2016.70.3959","volume":"35","author":"A Kuijer","year":"2017","unstructured":"Kuijer A, Straver M, den Dekker B, van Bommel ACM, Elias SG, Smorenburg CH, Wesseling J, Linn SC, Rutgers EJT, Siesling S, et al. Impact of 70-gene signature use on adjuvant chemotherapy decisions in patients with estrogen receptor-positive early breast cancer: results of a prospective cohort study. J Clin Oncol. 2017;35(24):2814\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4523_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10549-020-05683-6","volume":"182","author":"JEC van Steenhoven","year":"2020","unstructured":"van Steenhoven JEC, den Dekker BM, Kuijer A, van Diest PJ, Nieboer P, Zuetenhorst JM, Imholz ALT, Siesling S, van Dalen T. Patients\u2019 perceptions of 70-gene signature testing: commonly changing the initial inclination to undergo or forego chemotherapy and reducing decisional conflict. Breast Cancer Res Treat. 2020;182(1):107\u201315.","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"4523_CR13","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1200\/JCO.21.02019","volume":"40","author":"JMN Lopes Cardozo","year":"2022","unstructured":"Lopes Cardozo JMN, Drukker CA, Rutgers EJT, Schmidt MK, Glas AM, Witteveen A, Cardoso F, Piccart M, Esserman LJ, Poncet C, et al. Outcome of patients with an ultralow-risk 70-gene signature in the MINDACT trial. J Clin Oncol. 2022;40(12):1335\u201345.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4523_CR14","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10549-022-06618-z","volume":"194","author":"M Opdam","year":"2022","unstructured":"Opdam M, van der Noort V, Kleijn M, Glas A, Mandjes I, Kleiterp S, Hilbers FS, Kruger DT, Bins AD, de Jong PC, et al. Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature. Breast Cancer Res Treat. 2022;194(2):265\u201378.","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"4523_CR15","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.ccell.2021.05.009","volume":"39","author":"L Pusztai","year":"2021","unstructured":"Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, et al. Durvalumab with olaparib and paclitaxel for high-risk HER2\u2212negative stage II\/III breast cancer: results from the adaptively randomized I-SPY2 trial. Cancer Cell. 2021;39(7):989-998e985.","journal-title":"Cancer Cell"},{"issue":"7","key":"4523_CR16","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1245\/s10434-022-11666-2","volume":"29","author":"P Whitworth","year":"2022","unstructured":"Whitworth P, Beitsch PD, Pellicane JV, Baron PL, Lee LA, Dul CL, Nash CH 3rd, Murray MK, Richards PD, Gittleman M, et al. Age-independent preoperative chemosensitivity and 5-year outcome determined by combined 70- and 80-gene signature in a prospective trial in early-stage breast cancer. Ann Surg Oncol. 2022;29(7):4141\u201352.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"4523_CR17","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/cac2.12024","volume":"40","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhou Y, Mao F, Yao R, Sun Q. Ki-67 index, progesterone receptor expression, histologic grade and tumor size in predicting breast cancer recurrence risk: a consecutive cohort study. Cancer Commun. 2020;40(4):181\u201393.","journal-title":"Cancer Commun"},{"key":"4523_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.breast.2022.03.007","volume":"63","author":"C Wang","year":"2022","unstructured":"Wang C, Xu Y, Lin Y, Zhou Y, Mao F, Zhang X, Shen S, Zhang Y, Sun Q. Comparison of CTS5 risk model and 21-gene recurrence score assay in large-scale breast cancer population and combination of CTS5 and recurrence score to develop a novel nomogram for prognosis prediction. Breast. 2022;63:61\u201370.","journal-title":"Breast"},{"issue":"3","key":"4523_CR19","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10549-016-3949-y","volume":"159","author":"RA Nunes","year":"2016","unstructured":"Nunes RA, Wray L, Mete M, Herbolsheimer P, Smith KL, Bijelic L, Boisvert ME, Swain SM. Genomic profiling of breast cancer in African-American women using MammaPrint. Breast Cancer Res Treat. 2016;159(3):481\u20138.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"4523_CR20","doi-asserted-by":"publisher","first-page":"e173470","DOI":"10.1001\/jamaoncol.2017.3470","volume":"4","author":"M Tsai","year":"2018","unstructured":"Tsai M, Lo S, Audeh W, Qamar R, Budway R, Levine E, Whitworth P, Mavromatis B, Zon R, Oldham D, et al. Association of 70-gene signature assay findings with physicians\u2019 treatment guidance for patients with early breast cancer classified as intermediate risk by the 21-gene assay. JAMA Oncol. 2018;4(1):e173470.","journal-title":"JAMA Oncol"},{"issue":"4","key":"4523_CR21","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2001.19.4.980","volume":"19","author":"PM Ravdin","year":"2001","unstructured":"Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001;19(4):980\u201391.","journal-title":"J Clin Oncol"},{"issue":"19","key":"4523_CR22","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/JCO.2017.76.4258","volume":"36","author":"M Dowsett","year":"2018","unstructured":"Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thurlimann B, Colleoni M, Cuzick J. Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor-positive breast cancer treated with 5 years of endocrine therapy: CTS5. J Clin Oncol. 2018;36(19):1941\u20138.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4523_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/bjc.1982.62","volume":"45","author":"JL Haybittle","year":"1982","unstructured":"Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, Nicholson RI, Griffiths K. A prognostic index in primary breast cancer. Br J Cancer. 1982;45(3):361\u20136.","journal-title":"Br J Cancer"},{"issue":"1","key":"4523_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1513750","volume":"375","author":"JW Park","year":"2016","unstructured":"Park JW, Liu MC, Yee D, Yau C, van\u2019t Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, et al. Adaptive randomization of neratinib in early breast cancer. N Engl J Med. 2016;375(1):11\u201322.","journal-title":"N Engl J Med"},{"issue":"27","key":"4523_CR25","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817\u201326.","journal-title":"N Engl J Med"},{"issue":"25","key":"4523_CR26","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF, Lin NU, Perez EA, Goldstein LJ, Chia SKL, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336\u201347.","journal-title":"N Engl J Med"},{"issue":"1","key":"4523_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10549-013-2666-z","volume":"141","author":"JJ Carlson","year":"2013","unstructured":"Carlson JJ, Roth JA. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;141(1):13\u201322.","journal-title":"Breast Cancer Res Treat"},{"issue":"17","key":"4523_CR28","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1002\/cncr.32956","volume":"126","author":"A Ibraheem","year":"2020","unstructured":"Ibraheem A, Olopade OI, Huo D. Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National cancer data base. Cancer. 2020;126(17):4013\u201322.","journal-title":"Cancer"},{"issue":"2","key":"4523_CR29","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.clbc.2019.07.010","volume":"20","author":"SH Yoo","year":"2020","unstructured":"Yoo SH, Kim TY, Kim M, Lee KH, Lee E, Lee HB, Moon HG, Han W, Noh DY, Han SW, et al. Development of a nomogram to predict the recurrence score of 21-gene prediction assay in hormone receptor-positive early breast cancer. Clin Breast Cancer. 2020;20(2):98-107e101.","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"4523_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12967-021-02743-3","volume":"19","author":"J Yu","year":"2021","unstructured":"Yu J, Wu J, Huang O, He J, Zhu L, Chen W, Li Y, Chen X, Shen K. A nomogram to predict the high-risk RS in HR+\/HER2\u2212breast cancer patients older than 50 years of age. J Transl Med. 2021;19(1):75.","journal-title":"J Transl Med"},{"issue":"1","key":"4523_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-016-4093-4","volume":"162","author":"MR Harowicz","year":"2017","unstructured":"Harowicz MR, Robinson TJ, Dinan MA, Saha A, Marks JR, Marcom PK, Mazurowski MA. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset. Breast Cancer Res Treat. 2017;162(1):1\u201310.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"4523_CR32","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s12282-020-01100-4","volume":"27","author":"A Baltres","year":"2020","unstructured":"Baltres A, Al Masry Z, Zemouri R, Valmary-Degano S, Arnould L, Zerhouni N, Devalland C. Prediction of Oncotype DX recurrence score using deep multi-layer perceptrons in estrogen receptor-positive, HER2\u2212negative breast cancer. Breast Cancer. 2020;27(5):1007\u201316.","journal-title":"Breast Cancer"},{"issue":"4","key":"4523_CR33","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S1470-2045(21)00007-3","volume":"22","author":"M Piccart","year":"2021","unstructured":"Piccart M, van\u2019t Veer LJ, Poncet C, Lopes Cardozo JMN, Delaloge S, Pierga JY, Vuylsteke P, Brain E, Vrijaldenhoven S, Neijenhuis PA, et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 2021;22(4):476\u201388.","journal-title":"Lancet Oncol"},{"key":"4523_CR34","doi-asserted-by":"publisher","first-page":"734015","DOI":"10.3389\/fonc.2021.734015","volume":"11","author":"NN Phan","year":"2021","unstructured":"Phan NN, Hsu CY, Huang CC, Tseng LM, Chuang EY. Prediction of breast cancer recurrence using a deep convolutional neural network without region-of-interest labeling. Front Oncol. 2021;11:734015.","journal-title":"Front Oncol"},{"issue":"7","key":"4523_CR35","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.ejca.2012.01.034","volume":"48","author":"N Bhoo-Pathy","year":"2012","unstructured":"Bhoo-Pathy N, Yip CH, Hartman M, Saxena N, Taib NA, Ho GF, Looi LM, Bulgiba AM, van der Graaf Y, Verkooijen HM. Adjuvant! online is overoptimistic in predicting survival of Asian breast cancer patients. Eur J Cancer. 2012;48(7):982\u20139.","journal-title":"Eur J Cancer"},{"issue":"3","key":"4523_CR36","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/BF01840834","volume":"22","author":"MH Galea","year":"1992","unstructured":"Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham prognostic index in primary breast cancer. Breast Cancer Res Treat. 1992;22(3):207\u201319.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"4523_CR37","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/BF00666005","volume":"32","author":"I Balslev","year":"1994","unstructured":"Balslev I, Axelsson CK, Zedeler K, Rasmussen BB, Carstensen B, Mouridsen HT. The Nottingham prognostic index applied to 9149 patients from the studies of the Danish breast cancer cooperative group (DBCG). Breast Cancer Res Treat. 1994;32(3):281\u201390.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"4523_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4097\/kja.21209","volume":"75","author":"FS Nahm","year":"2022","unstructured":"Nahm FS. Receiver operating characteristic curve: overview and practical use for clinicians. Korean J Anesthesiol. 2022;75(1):25\u201336.","journal-title":"Korean J Anesthesiol"},{"issue":"6","key":"4523_CR39","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0272989X06295361","volume":"26","author":"AJ Vickers","year":"2006","unstructured":"Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26(6):565\u201374.","journal-title":"Med Decis Making"},{"key":"4523_CR40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1472-6947-8-53","volume":"8","author":"AJ Vickers","year":"2008","unstructured":"Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak. 2008;8:53.","journal-title":"BMC Med Inform Decis Mak"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04523-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-04523-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-04523-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T22:01:54Z","timestamp":1699567314000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-04523-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4523"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-04523-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2650533\/v1","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]},"assertion":[{"value":"3 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in our studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. For this type of study, formal consent is not required. This retrospective study was approved by the Ethics Committee of the Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors have declared that no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"798"}}